Meta分析他克莫司与环孢素A治疗肺移植患者术后的排斥反应
作者：苏兰;吴斌;朱小牧;饶凡;
Author：
收稿日期： 年卷（期）页码：2010,25(04):-498-501
期刊名称：华西药学杂志
Journal Name：WEST CHINA JOURNAL OF PHARMACEUTICAL SCIENCES
关键字：他克莫司;环孢素A;肺移植;Meta分析;排斥反应
Key words：
基金项目：
中文摘要
目的分析他克莫司(FK)与环孢素A(CSA)在治疗肺移植患者术后排斥反应的疗效和安全性。方法计算机检索Medline、Embase、Sci、Cochrane图书馆及CBM数据库,纳入FK对比CSA治疗肺移植患者术后排斥反应的随机对照试验(RCT);对纳入文献进行方法学质量评价和Meta分析。结果共纳入4个RCT(331例受试者),分析显示:两组急性排斥反应的发生率差异有统计学意义,FK组新发糖尿病患者多于CSA组,从CSA组转用其方式治疗的患者多于FK组;1年内总存活率及梗阻性支气管炎的发生率差异无统计学意义;肾功能两组相似。结论基于当前证据,肺移植后的抗排斥反应治疗,FK与CSA比较能减少急性排斥反应的发生,但会导致更多新发糖尿病患者。
参考文献
[1]Knoop C,Haverich A,Fischer S.Immunosuppressive therapy after human lung transplantation[J].Eur Respir J,2004,23:159-171.
[2]Trulock EP,Christie JD,Edwards LB,et al.Registry of the in-ternational society for heart and lung transplantation:twenty-fourth official adult lung and heart-lung transplantation report-2007[J].J Heart Lung Transplant,2007,26:782-795.
[3]Sharples LD,McNeil K,Stewart S,et al.Risk factors for bron-chiolitis obliterans:a systematic review of recent publications[J].J Heart Lung Transplant,2002,21:271-281.
[4]Knoop C,Estenne M.Acute and chronic rejection after lung transplantation[J].Semin Respir Crit Care Med,2006,27:521.
[5]Fan Y,Xiao Y,Weng Y G,et al.Tacrolimus Versus Cyclospo-rine Microemulsion for Heart Transplant Recipients:A Meta-analysis[J].J Heart Lung Transplant,2009,28:58-66.
[6]McAlister VC,Haddad E,Renouf E,et al.Cyclosporin versus tacrolimus as primary immunosuppressant after liver transplanta-tion:a meta-analysis[J].Am J Transplant,2006,6:1578-85.
[7]Jadad AR,Moore RA,Carroll D,et al.Assessing the quality of reports of randomized clinical trials:is blinding necessary[J].Control Clin Trials,1996,17:1-12.
[8]Altman DG,Schulz KF.Statistics notes:concealing treatment al-location in randomized trials[J].Br Med J,2001,323:446-447.
[9]Moher D,Pham B,Jones A,et al.Does quality of reports of randomised trials affect estimates of intervention efficacy reported in meta-analyses[J].Lancet,1998,352:609-613.
[10]Cochrane WG..The combination of estimates from different experiments[J].Biometrics,1954,10:101-29.
[11]Griffith BP,Bando K,Hardesty RL,et al.A prospective ran-domized trial of FK506versus cyclosporine after human pulmona-ry transplantation[J].Transplantation,1994,57:848-851.
[12]Keenan RJ,Konishi H,Kawai A,et al.Clinical trial of tacroli-mus versus cyclosporine in lung transplantation[J].Ann Thorac Surg,1995,60:580-584.
[13]Treede H,Klepetko W,Reichenspurner H,et al.Tacrolimus versus cyclosporine after lung transplantation:a prospective,open,randomized two-center trial comparing two different im-munosuppressive protocols[J].J Heart Lung Transplant,2001,20:511-517.
[14]Zuckermann A,Reichenspurner H,Birsan T,et al.Cyclospo-rine A versus tacrolimus in combination with mycophenolate mof-etil and steroids as primary immunosuppression after lung trans-plantation:one-year results of a2-center prospective random-ized trial[J].J Thorac Cardiovasc Surg,2003,125:891-900.
[15]Hachem RR,Yusen RD,Chakinala MM,et al.A randomized controlled trial of tacrolimus versus cyclosporine after lung trans-plantation[J].J Heart Lung Transplant,2007,26:1012-1018.
[16]Khan KS,Daya S,Jadad AR.The importance of quality of pri-mary studies in producing unbiased systematic reviews[J].Arch Intern Med,1996,156:661-666.
【关闭】
